title: Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
abstract: Prothrombin complex concentrates (PCCs) and, more recently, activated prothrombin complex concentrates (APCCs), are widely used for the treatment of active bleeding in haemophiliacs with inhibitors. Myocardial infarction (MI), associated with the use of these concentrates, is a well-recognized, but uncommon, complication. We review the 14 previous cases published in the literature and describe two additional patients. MI related to the use of activated and non-activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate. The most frequent pathological finding is myocardial haemorrhage, with no evidence of coronary artery atheroma or thrombosis. The management of further bleeding in these patients is difficult. We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following PCC-related MI.
authors: Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
authors: R E
authors: RE
authors: Hough
authors: K K
authors: KK
authors: Hampton
authors: F E
authors: FE
authors: Preston
authors: K S
authors: KS
authors: Channer
authors: J
authors: J
authors: West
authors: M
authors: M
authors: Makris
mesh_terms: D000005:Abdomen; D000328:Adult; D000368:Aged; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D001779:Blood Coagulation Factors / Q000009:adverse effects* / Q000627:therapeutic use; D005169:Factor VIII; D015942:Factor VIIa / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000188:drug therapy*; D006406:Hematoma / Q000188:drug therapy; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007719:Knee Joint; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D005169:Factor VIII; D015942:Factor VIIa